IPC분류정보
국가/구분 |
United States(US) Patent
공개
|
국제특허분류(IPC7판) |
|
출원번호 |
16829917
(2020-03-25)
|
공개번호 |
20200271674
(2020-08-27)
|
발명자
/ 주소 |
- Royall, Donald R.
- Palmer, Raymond F.
|
출원인 / 주소 |
- The Board of Regents of The University of Texas System
|
인용정보 |
피인용 횟수 :
0 인용 특허 :
0 |
초록
▼
Certain embodiments are directed to methods of identifying dementia in subjects comprising, measuring serum levels of one or more of interferon gamma, IL-10, IL-12p40, IL-13, alpha 2 macroglobulin, beta 2 microglobulin, pancreatic polypeptide, prolactin, stem cell factor, thrombopoietin, and Von Wil
Certain embodiments are directed to methods of identifying dementia in subjects comprising, measuring serum levels of one or more of interferon gamma, IL-10, IL-12p40, IL-13, alpha 2 macroglobulin, beta 2 microglobulin, pancreatic polypeptide, prolactin, stem cell factor, thrombopoietin, and Von Willebrand Factor and identifying a subject as having dementia if the levels of the biomarkers is increased.
대표청구항
▼
1-9. (canceled) 10. A method for treating a human subject comprising, (a) obtaining a blood sample from said subject;(b) contacting the biological sample with reagents that specifically bind and form a complex with IL-13 and alpha 2 macroglobulin biomarkers forming a reagent biomarker complex;(c) de
1-9. (canceled) 10. A method for treating a human subject comprising, (a) obtaining a blood sample from said subject;(b) contacting the biological sample with reagents that specifically bind and form a complex with IL-13 and alpha 2 macroglobulin biomarkers forming a reagent biomarker complex;(c) detecting the reagent biomarker complex of IL-13 and alpha 2 macroglobulin and determining the level of the biomarkers in the sample; and(d) administering treatment to the subject when the level of the biomarkers in the sample is increased with respect to a control level. 11. The method of claim 1, comprising treating a mild cognitive impairment (MCI) condition. 12. The method of claim 1, comprising treating a dementia condition. 13. The method of claim 3, comprising treating an early stage dementia condition. 14. The method of claim 1, further comprising identifying dementia in said subject based on the step of determining the level of said biomarkers. 15. The method of claim 5, comprising identifying early stage dementia in said subject by determining increased serum levels of any of interferon gamma, IL-10, IL-12p40, IL-13, alpha 2 macroglobulin, beta 2 microglobulin, pancreatic polypeptide, prolactin, stem cell factor, thrombopoietin, and Von Willebrand Factor for dementia. 16. The method of claim 1, further comprising selecting said biomarkers based on a linear regression. 17. The method of claim 1, wherein said biomarkers are independent of an ethnicity of said subject.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.